Market OpportunitiesBerGenBio has an opportunity to capture market share by targeting the STK11 mutation in cancer, particularly relevant for lung cancer patients with significant unmet medical need.

Bears Say

Partnership ChallengesIn 2022, BerGenBio announced it would not continue the internal development of tilvestamab due to an inability to secure an attractive partnership on favorable terms.

Product Development IssuesADC Therapeutics informed BerGenBio that the therapeutic window for ADCT-601 is too narrow, likely due to toxicities, impacting its development.

BerGenBio ASA News

BerGenBio Announces Delays in Merger and Rights Issue Timeline

The latest update is out from BerGenBio ASA ( ($BRRGF) ). BerGenBio ASA announced a delay in the...

2d ago

BerGenBio ASA Merges with Oncoinvent to Boost Cancer Innovation

Bergenbio Asa ( ($BRRGF) ) has released its Q2 earnings. Here is a breakdown of the information Bergenbio...

30d ago

BerGenBio ASA Announces Strategic Merger with Oncoinvent ASA

BerGenBio ASA ( ($BRRGF) ) has provided an update. BerGenBio ASA announced its financial results for the first...

1M ago

BerGenBio ASA Announces NOK 130 Million Rights Issue Post-Merger

BerGenBio ASA ( ($BRRGF) ) has issued an update. BerGenBio ASA has announced a fully underwritten rights issue...

2M ago

BerGenBio ASA Approves Merger Plan with Oncoinvent

BerGenBio ASA ( ($BRRGF) ) has shared an announcement. BerGenBio ASA has announced the approval of a merger...

2M ago

BerGenBio ASA Announces Virtual Extraordinary General Meeting

BerGenBio ASA ( ($BRRGF) ) just unveiled an announcement. BerGenBio ASA has announced that it will hold an...

3M ago

BerGenBio ASA Announces NOK 130 Million Rights Issue Post-Merger

BerGenBio ASA ( ($BRRGF) ) has issued an announcement. BerGenBio ASA has announced a fully underwritten rights issue...

3M ago

BerGenBio ASA Announces NOK 130 Million Rights Issue Post-Merger

An update from BerGenBio ASA ( ($BRRGF) ) is now available. BerGenBio ASA has announced a fully underwritten...

3M ago

BerGenBio ASA Approves Board Resolutions in Annual Meeting

BerGenBio ASA ( ($BRRGF) ) has shared an update. BerGenBio ASA conducted its annual general meeting digitally, where...

3M ago

BerGenBio Continues Strategic Review and Ends Bemcentinib Development

BerGenBio ASA ( ($BRRGF) ) has shared an update. BerGenBio ASA has announced the continuation of its strategic...

4M ago

BerGenBio target adjusted to NOK 38 from NOK 70 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on BerGenBio to NOK 38 from NOK 70...

1y ago

BerGenBio downgraded to Sell on ‘detrimental’ financing at DNB

DNB Markets analyst Geir Hiller Holom downgraded BerGenBio to Sell from Hold with a price target of NOK...

2y ago

BerGenBio downgraded to Sell from Hold at DNB Markets

DNB Markets downgraded BerGenBio to Sell from Hold with a NOK 1 price target. Published first on TheFly...

2y ago

BerGenBio upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis upgraded BerGenBio to Buy from Neutral with a NOK 30 price target. "Now...

3y ago

BRRGF

BRRGF FAQ

What was Bergenbio Asa’s price range in the past 12 months?

Bergenbio Asa lowest stock price was $0.03 and its highest was $0.03 in the past 12 months.

What is Bergenbio Asa’s market cap?

Bergenbio Asa’s market cap is $4.72M.

When is Bergenbio Asa’s upcoming earnings report date?

Bergenbio Asa’s upcoming earnings report date is Nov 19, 2025 which is in 61 days.

How were Bergenbio Asa’s earnings last quarter?

Bergenbio Asa released its earnings results on Aug 20, 2025. The company reported -$0.137 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.137.

Is Bergenbio Asa overvalued?

According to Wall Street analysts Bergenbio Asa’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bergenbio Asa pay dividends?

Bergenbio Asa does not currently pay dividends.

What is Bergenbio Asa’s EPS estimate?

Bergenbio Asa’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bergenbio Asa have?

Bergenbio Asa has 39,087,116 shares outstanding.

What happened to Bergenbio Asa’s price movement after its last earnings report?

Bergenbio Asa reported an EPS of -$0.137 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Bergenbio Asa?

Currently, no hedge funds are holding shares in BRRGF

Company Description

Bergenbio Asa

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.